Intravenous and intrathecal onasemnogene abeparvovec gene therapy in symptomatic and presymptomatic SMA: long-term follow-up study

被引：0
|
作者：
Darras, B. [1 ]
Farrar, M. [2 ,3 ]
Mercuri, E. [4 ,5 ]
Strauss, K. [6 ,7 ,8 ]
Day, J. [9 ]
Chien, Y. [10 ]
Masson, R. [11 ]
Bernardo, R. [12 ]
Alecu, I. [13 ]
Dodd, N. [14 ]
Mehl, L. [15 ]
Connolly, A. [16 ,17 ]
机构：
[1] Harvard Med Sch, Boston Childrens Hosp, Boston, MA USA
[2] Sydney Childrens Hosp Network, Sydney, NSW, Australia
[3] UNSW Sydney, Sch Clin Med, UNSW Med & Hlth, Sydney, NSW, Australia
[4] Catholic Univ, Dept Paediat Neurol, Rome, Italy
[5] Catholic Univ, Nemo Clin Ctr, Rome, Italy
[6] Clin Special Children, Strasburg, PA USA
[7] Penn Med Lancaster Gen Hosp, Lancaster, PA USA
[8] Univ Massachusetts, Sch Med, Worcester, MA USA
[9] Stanford Univ, Med Ctr, Stanford, CA USA
[10] Natl Taiwan Univ Hosp, Taipei, Taiwan
[11] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy
[12] Novartis Global Drug Dev Neurosci & Gene Therap, E Hanover, NJ USA
[13] Novartis Pharmaceut, Basel, Switzerland
[14] Novartis Gene Therapies Inc, Bannockburn, IL USA
[15] Novartis, BioMed Res, Cambridge, MA USA
[16] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH USA
[17] Ohio State Univ, Coll Med, Columbus, OH USA
来源：
NEUROMUSCULAR DISORDERS | 2024年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
179P
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update
    Strauss, K.
    Farrar, M.
    Swoboda, K.
    Saito, K.
    Chiriboga, C.
    Finkel, R.
    Iannaccone, S.
    Krueger, J.
    Kwon, J.
    McMillan, H.
    Servais, L.
    Mendell, J.
    Parsons, J.
    Scoto, M.
    Shieh, P.
    Zaidman, C.
    Schultz, M.
    Ogrinc, F.
    Group, S.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S122 - S122
  • [12] Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial
    Mendell, J.
    Shell, R.
    Lehman, K.
    McColly, M.
    Lowes, L.
    Alfano, L.
    Miller, N.
    Iammarino, M.
    Church, K.
    Ogrinc, F.
    Ouyang, H.
    Kernbauer, E.
    Shah, S.
    L'Italien, J.
    Sproule, D.
    Feltner, D.
    Al-Zaidy, S.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S184 - S184
  • [13] Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial
    Mendell, J. R.
    Shell, R.
    Lehman, K. J.
    McColly, M.
    Lowes, L. P.
    Alfano, L. N.
    Miller, N. F.
    Iammarino, M. A.
    Church, K.
    Spector, S. A.
    Ogrinc, F. G.
    Ouyang, H.
    Kernbauer, E.
    Shah, S.
    L'Italien, J.
    Sproule, D. M.
    Feltner, D. E.
    Al-Zaidy, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [14] Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Onasemnogene Abeparvovec Phase 1/2a Clinical Trial
    Mendell, J.
    Shell, R.
    Lehman, K.
    McColly, M.
    Lowes, L.
    Alfano, L.
    Miller, N.
    Iammarino, M.
    Church, K.
    Ogrinc, F.
    Ouyang, H.
    Kernbauer, E.
    Shah, S.
    L'Italien, J.
    Sproule, D.
    Feltner, D.
    Al-Zaidy, S.
    ANNALS OF NEUROLOGY, 2019, 86 : S126 - S126
  • [15] Onasemnogene Abeparvovec-xioi Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update
    Strauss, K. A.
    Farrar, M. A.
    Swoboda, K. J.
    Saito, K.
    Chiriboga, C. A.
    Finkel, R. S.
    Iannaccone, S. T.
    Krueger, J. M.
    Kwon, J. M.
    McMillan, H. J.
    Servais, L.
    Mendell, J. R.
    Parsons, J.
    Scoto, M.
    Shieh, P. B.
    Zaidman, C.
    Schultz, M.
    Baldinetti, F.
    Ogrinc, F. G.
    Kavanagh, S.
    Feltner, D. E.
    Tauscher-Wisniewski, S.
    McGill, B. E.
    Sproule, D. M.
    Muntoni, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 165 - 166
  • [16] Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) in Pre-symptomatic Spinal Muscular Atrophy (SMA)
    Schultz, M.
    Swoboda, K.
    Farrar, M.
    McMillan, H.
    Parsons, J.
    Kernbauer, E.
    Farrow, M.
    Ogrinc, F.
    Kavanagh, S.
    Feltner, D.
    McGill, B.
    Spector, S.
    L'Italien, J.
    Sproule, D.
    Strauss, K.
    ANNALS OF NEUROLOGY, 2019, 86 : S133 - S133
  • [17] Onasemnogene abeparvovec gene-replacement therapy (GRT) in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update
    Strauss, K. A.
    Swoboda, K. J.
    Farrar, M. A.
    McMillan, H. J.
    Parsons, J.
    Krueger, J. M.
    Iannaccone, S. T.
    Chiriboga, C. A.
    Kwon, J. M.
    Saito, K.
    Scoto, M.
    Baldinetti, F.
    Schultz, M.
    Kernbauer, E.
    Farrow, M.
    Ogrinc, F. G.
    Kavanagh, S.
    Feltner, D. E.
    McGill, B. E.
    Spector, S. A.
    L'Italien, J.
    Sproule, D. M.
    Muntoni, F.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [18] Onasemnogene abeparvovec gene-replacement therapy (GRT) in pre-symptomatic spinal muscular atrophy (SMA)
    Schultz, M.
    Swoboda, K.
    Farrar, M.
    McMillan, H.
    Parsons, J.
    Kernbauer, E.
    Farrow, M.
    Ogrinc, F.
    Kavanagh, S.
    Feltner, D.
    McGill, B.
    Spector, S.
    L'Italien, J.
    Sproule, D.
    Strauss, K.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S183 - S183
  • [19] Long-term follow-up of hemophilia gene therapy in dogs
    Le Bras, Alexandra
    LAB ANIMAL, 2021, 50 (01) : 14 - 14
  • [20] Long-term follow-up of hemophilia gene therapy in dogs
    Alexandra Le Bras
    Lab Animal, 2021, 50 : 14 - 14
12345